Semmelweis University, 1st Department of Internal Medicine, Oncology Section; Tömő u. 25-29, 1083 Budapest, Hungary.
Anticancer Res. 2014 Mar;34(3):1275-80.
First-line bevacizumab-paclitaxel therapy demonstrated a median progression-free survival (PFS) of 11 months in three randomized phase III trials on metastatic breast cancer (mBC) (E2100, TURANDOT and CALGB 40502). We assessed the efficacy and safety of bevacizumab-paclitaxel in a routine oncology practice study.
Patients with previously untreated mBC received bevacizumab-paclitaxel according to the approved indication in Hungary. The primary end-point was PFS. Secondary end-points included time-to-treatment discontinuation, 1-year survival rate, PFS in patients with triple-negative breast cancer (TNBC) and safety.
Median PFS in the 220 treated patients was 9.3 (95%CI 7.8-10.8) months. The 1-year survival rate was 68%. In patients with TNBC (N=106), median PFS was 8.3 months (95%CI 7.8-8.8). Adverse events were consistent with the established safety profile of bevacizumab-paclitaxel.
Bevacizumab-paclitaxel is an active and well-tolerated first-line treatment for mBC, with notable activity in TNBC.
贝伐珠单抗联合紫杉醇一线治疗转移性乳腺癌（mBC）的三项随机 III 期临床试验（E2100、TURANDOT 和 CALGB 40502）显示中位无进展生存期（PFS）为 11 个月。我们在常规肿瘤学实践研究中评估了贝伐珠单抗联合紫杉醇的疗效和安全性。
未经治疗的 mBC 患者按照匈牙利的批准适应证接受贝伐珠单抗联合紫杉醇治疗。主要终点是 PFS。次要终点包括治疗中止时间、1 年生存率、三阴性乳腺癌（TNBC）患者的 PFS 和安全性。
220 例接受治疗患者的中位 PFS 为 9.3（95%CI 7.8-10.8）个月。1 年生存率为 68%。在 TNBC 患者（N=106）中，中位 PFS 为 8.3 个月（95%CI 7.8-8.8）。不良事件与贝伐珠单抗联合紫杉醇的既定安全性特征一致。
贝伐珠单抗联合紫杉醇是 mBC 的一种有效且耐受良好的一线治疗方法，在 TNBC 中具有显著的活性。
